Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Reisa Anne Sperling, M.D.

Co-Author

This page shows the publications co-authored by Reisa Sperling and Dorene Rentz.
Connection Strength

14.998
  1. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12.
    View in: PubMed
    Score: 0.689
  2. Establishing Clinical Relevance in Preclinical Alzheimer's Disease. J Prev Alzheimers Dis. 2015 Jun; 2(2):85-87.
    View in: PubMed
    Score: 0.654
  3. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011 Jul; 49(9):2776-83.
    View in: PubMed
    Score: 0.496
  4. IQ-based norms for highly intelligent adults. Clin Neuropsychol. 2006 Dec; 20(4):637-48.
    View in: PubMed
    Score: 0.363
  5. Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology. 2021 04 06; 96(14):e1844-e1854.
    View in: PubMed
    Score: 0.243
  6. Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. J Prev Alzheimers Dis. 2021; 8(3):257-262.
    View in: PubMed
    Score: 0.241
  7. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. J Prev Alzheimers Dis. 2021; 8(1):59-67.
    View in: PubMed
    Score: 0.241
  8. Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. Ann Neurol. 2020 11; 88(5):921-932.
    View in: PubMed
    Score: 0.235
  9. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.225
  10. Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neuroimage Clin. 2019; 24:102097.
    View in: PubMed
    Score: 0.223
  11. Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cereb Cortex. 2019 07 22; 29(8):3445-3456.
    View in: PubMed
    Score: 0.218
  12. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.214
  13. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.210
  14. Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. Alzheimers Res Ther. 2019 01 10; 11(1):4.
    View in: PubMed
    Score: 0.210
  15. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.210
  16. Amyloid-associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y). 2018; 4:444-449.
    View in: PubMed
    Score: 0.205
  17. Age-Related Increases in Tip-of-the-tongue are Distinct from Decreases in Remembering Names: A Functional MRI Study. Cereb Cortex. 2017 09 01; 27(9):4339-4349.
    View in: PubMed
    Score: 0.191
  18. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin. 2017; 15:408-414.
    View in: PubMed
    Score: 0.187
  19. Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia. 2017 06; 100:164-170.
    View in: PubMed
    Score: 0.187
  20. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology. 2017 May 02; 88(18):1759-1767.
    View in: PubMed
    Score: 0.186
  21. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. Neuropsychologia. 2017 05; 99:343-349.
    View in: PubMed
    Score: 0.186
  22. Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav. 2017 04; 11(2):383-390.
    View in: PubMed
    Score: 0.186
  23. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017 Apr 11; 88(15):1431-1438.
    View in: PubMed
    Score: 0.185
  24. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012.
    View in: PubMed
    Score: 0.184
  25. Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. J Prev Alzheimers Dis. 2017; 4(2):81-86.
    View in: PubMed
    Score: 0.182
  26. Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries. J Prev Alzheimers Dis. 2017; 4(1):3-11.
    View in: PubMed
    Score: 0.182
  27. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry. 2016 Dec 01; 73(12):1230-1237.
    View in: PubMed
    Score: 0.181
  28. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol. 2016 Oct 01; 73(10):1185-1191.
    View in: PubMed
    Score: 0.179
  29. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016 Jan; 79(1):110-9.
    View in: PubMed
    Score: 0.170
  30. The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. J Prev Alzheimers Dis. 2015 Dec; 2(4):242-253.
    View in: PubMed
    Score: 0.169
  31. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology. 2016 07; 30(5):624-30.
    View in: PubMed
    Score: 0.169
  32. Subjective cognitive concerns, amyloid-ß, and neurodegeneration in clinically normal elderly. Neurology. 2015 Jul 07; 85(1):56-62.
    View in: PubMed
    Score: 0.164
  33. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015 Jul; 73:169-75.
    View in: PubMed
    Score: 0.163
  34. Amyloid-ß deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015 Apr; 138(Pt 4):1023-35.
    View in: PubMed
    Score: 0.160
  35. Functional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive Impairment. Curr Alzheimer Res. 2015; 12(5):493-502.
    View in: PubMed
    Score: 0.159
  36. Synergistic effect of ß-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014 Nov; 71(11):1379-85.
    View in: PubMed
    Score: 0.157
  37. Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory. Clin Neuropsychol. 2014; 28(5):771-85.
    View in: PubMed
    Score: 0.152
  38. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13.
    View in: PubMed
    Score: 0.150
  39. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1642-51.
    View in: PubMed
    Score: 0.150
  40. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 41(3):719-28.
    View in: PubMed
    Score: 0.148
  41. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. Alzheimers Res Ther. 2013; 5(6):58.
    View in: PubMed
    Score: 0.147
  42. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012 Nov 14; 32(46):16233-42.
    View in: PubMed
    Score: 0.137
  43. Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease? Neurodegener Dis Manag. 2012 Oct 01; 2(5):483-491.
    View in: PubMed
    Score: 0.136
  44. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct; 50(12):2880-2886.
    View in: PubMed
    Score: 0.135
  45. Validation of the Face Name Associative Memory Exam in cognitively normal older individuals. J Clin Exp Neuropsychol. 2012; 34(6):580-7.
    View in: PubMed
    Score: 0.131
  46. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J Neurosci. 2011 Nov 30; 31(48):17680-8.
    View in: PubMed
    Score: 0.128
  47. Specific subjective memory complaints in older persons may indicate poor cognitive function. J Am Geriatr Soc. 2011 Sep; 59(9):1612-7.
    View in: PubMed
    Score: 0.126
  48. Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials. Arch Neurol. 2011 May; 68(5):599-606.
    View in: PubMed
    Score: 0.123
  49. Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging. 2012 Jul; 33(7):1237-52.
    View in: PubMed
    Score: 0.121
  50. Reliability of functional magnetic resonance imaging associative encoding memory paradigms in non-demented elderly adults. Hum Brain Mapp. 2011 Dec; 32(12):2027-44.
    View in: PubMed
    Score: 0.121
  51. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010 Jun 01; 107(22):10256-61.
    View in: PubMed
    Score: 0.115
  52. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010 Mar; 12(1):27-43.
    View in: PubMed
    Score: 0.114
  53. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010 Mar; 67(3):353-64.
    View in: PubMed
    Score: 0.114
  54. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009 Jul 30; 63(2):178-88.
    View in: PubMed
    Score: 0.109
  55. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008 Feb 12; 105(6):2181-6.
    View in: PubMed
    Score: 0.098
  56. Relationship of fMRI activation to clinical trial memory measures in Alzheimer disease. Neurology. 2007 Sep 25; 69(13):1331-41.
    View in: PubMed
    Score: 0.096
  57. Intelligence quotient-adjusted memory impairment is associated with abnormal single photon emission computed tomography perfusion. J Int Neuropsychol Soc. 2007 Sep; 13(5):821-31.
    View in: PubMed
    Score: 0.096
  58. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006 Oct 04; 26(40):10222-31.
    View in: PubMed
    Score: 0.090
  59. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005 Aug 09; 65(3):404-11.
    View in: PubMed
    Score: 0.083
  60. Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology. 2004 Jan; 18(1):38-49.
    View in: PubMed
    Score: 0.074
  61. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Jan; 74(1):44-50.
    View in: PubMed
    Score: 0.069
  62. Use of a false recognition paradigm in an Alzheimer's disease clinical trial: a pilot study. Am J Alzheimers Dis Other Demen. 2002 Mar-Apr; 17(2):93-100.
    View in: PubMed
    Score: 0.065
  63. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Netw Open. 2021 Jul 01; 4(7):e2114364.
    View in: PubMed
    Score: 0.062
  64. Plasma IL-12/IFN-? axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimers Dement. 2021 Jun 23.
    View in: PubMed
    Score: 0.062
  65. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021 May 05.
    View in: PubMed
    Score: 0.062
  66. The impact of COVID-19 on the well-being and cognition of older adults living in the United States and Latin America. EClinicalMedicine. 2021 May; 35:100848.
    View in: PubMed
    Score: 0.062
  67. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.060
  68. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.060
  69. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021 01 26; 96(4):e619-e631.
    View in: PubMed
    Score: 0.060
  70. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118.
    View in: PubMed
    Score: 0.059
  71. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.059
  72. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.059
  73. Correction: Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 Oct; 25(10):2644.
    View in: PubMed
    Score: 0.059
  74. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 09 10; 12(1):104.
    View in: PubMed
    Score: 0.059
  75. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.059
  76. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 08 21; 12(1):99.
    View in: PubMed
    Score: 0.059
  77. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology. 2020 09 08; 95(10):e1312-e1321.
    View in: PubMed
    Score: 0.058
  78. The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology. 2020 05 05; 94(18):e1916-e1928.
    View in: PubMed
    Score: 0.057
  79. Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiol Aging. 2020 09; 93:124-130.
    View in: PubMed
    Score: 0.057
  80. Associations of Widowhood and ß-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Netw Open. 2020 02 05; 3(2):e200121.
    View in: PubMed
    Score: 0.057
  81. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.056
  82. Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):330-332.
    View in: PubMed
    Score: 0.056
  83. Associations of Physical Activity and ß-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019 Oct 01; 76(10):1203-1210.
    View in: PubMed
    Score: 0.055
  84. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.055
  85. Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Netw Open. 2019 08 02; 2(8):e198964.
    View in: PubMed
    Score: 0.055
  86. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019 Aug 01; 76(8):915-924.
    View in: PubMed
    Score: 0.055
  87. Social Engagement and Amyloid-ß-Related Cognitive Decline in Cognitively Normal Older Adults. Am J Geriatr Psychiatry. 2019 11; 27(11):1247-1256.
    View in: PubMed
    Score: 0.054
  88. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019 06; 78:178-185.
    View in: PubMed
    Score: 0.053
  89. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. Alzheimers Res Ther. 2019 01 31; 11(1):14.
    View in: PubMed
    Score: 0.053
  90. Vascular Risk and ß-Amyloid Are Synergistically Associated with Cortical Tau. Ann Neurol. 2019 02; 85(2):272-279.
    View in: PubMed
    Score: 0.052
  91. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. J Alzheimers Dis. 2019; 67(2):757-768.
    View in: PubMed
    Score: 0.052
  92. Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry. 2018 12 18; 8(1):282.
    View in: PubMed
    Score: 0.052
  93. Interactive Associations of Vascular Risk and ß-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol. 2018 09 01; 75(9):1124-1131.
    View in: PubMed
    Score: 0.051
  94. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2020 10; 25(10):2599-2607.
    View in: PubMed
    Score: 0.051
  95. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.050
  96. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.050
  97. The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. Am J Geriatr Psychiatry. 2018 08; 26(8):896-904.
    View in: PubMed
    Score: 0.050
  98. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018 03; 21(3):424-431.
    View in: PubMed
    Score: 0.049
  99. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry. 2018 06 01; 175(6):530-537.
    View in: PubMed
    Score: 0.049
  100. A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease. J Alzheimers Dis. 2018; 65(1):107-115.
    View in: PubMed
    Score: 0.049
  101. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global ß-Amyloid Burden. JAMA Neurol. 2017 12 01; 74(12):1455-1463.
    View in: PubMed
    Score: 0.049
  102. The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst). 2018; 10:121-129.
    View in: PubMed
    Score: 0.049
  103. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017 Nov; 3(4):668-677.
    View in: PubMed
    Score: 0.048
  104. Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. Age Ageing. 2017 11 01; 46(6):988-993.
    View in: PubMed
    Score: 0.048
  105. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 04; 89(1):29-37.
    View in: PubMed
    Score: 0.047
  106. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017 Apr; 81(4):583-596.
    View in: PubMed
    Score: 0.046
  107. Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. Am J Geriatr Psychiatry. 2017 Jul; 25(7):683-693.
    View in: PubMed
    Score: 0.046
  108. Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985.
    View in: PubMed
    Score: 0.046
  109. The influence of demographic factors on subjective cognitive concerns and beta-amyloid. Int Psychogeriatr. 2017 04; 29(4):645-652.
    View in: PubMed
    Score: 0.045
  110. Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. J Alzheimers Dis. 2016 06 18; 53(3):1097-105.
    View in: PubMed
    Score: 0.044
  111. Loneliness, depression and cognitive function in older U.S. adults. Int J Geriatr Psychiatry. 2017 05; 32(5):564-573.
    View in: PubMed
    Score: 0.044
  112. Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiol Aging. 2016 Apr; 40:61-67.
    View in: PubMed
    Score: 0.043
  113. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S63-86.
    View in: PubMed
    Score: 0.042
  114. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology. 2015 Jul 07; 85(1):48-55.
    View in: PubMed
    Score: 0.041
  115. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015 May 26; 84(21):2153-60.
    View in: PubMed
    Score: 0.041
  116. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017 01; 144(Pt B):255-258.
    View in: PubMed
    Score: 0.040
  117. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr; 72(4):446-54.
    View in: PubMed
    Score: 0.040
  118. Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. J Alzheimers Dis. 2015; 46(3):727-35.
    View in: PubMed
    Score: 0.040
  119. Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. J Alzheimers Dis. 2015; 46(1):63-73.
    View in: PubMed
    Score: 0.040
  120. Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord. 2015 Jan-Mar; 29(1):18-25.
    View in: PubMed
    Score: 0.040
  121. The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. J Alzheimers Dis. 2015; 47(2):421-32.
    View in: PubMed
    Score: 0.040
  122. Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals. J Neuropsychiatry Clin Neurosci. 2015; 27(1):e22-7.
    View in: PubMed
    Score: 0.039
  123. Subjective cognitive concerns, episodic memory, and the APOE e4 allele. Alzheimers Dement. 2014 Nov; 10(6):752-759.e1.
    View in: PubMed
    Score: 0.039
  124. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70.
    View in: PubMed
    Score: 0.039
  125. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 Nov; 10(6):844-52.
    View in: PubMed
    Score: 0.038
  126. Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014 May 20; 82(20):1760-7.
    View in: PubMed
    Score: 0.038
  127. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 42(1):291-300.
    View in: PubMed
    Score: 0.037
  128. SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res. 2014; 11(8):785-91.
    View in: PubMed
    Score: 0.037
  129. Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2014; 11(9):853-61.
    View in: PubMed
    Score: 0.037
  130. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014 Nov; 22(11):1168-79.
    View in: PubMed
    Score: 0.036
  131. Apathy is associated with increased amyloid burden in mild cognitive impairment. J Neuropsychiatry Clin Neurosci. 2013; 25(4):302-7.
    View in: PubMed
    Score: 0.035
  132. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord. 2012; 34(2):96-111.
    View in: PubMed
    Score: 0.034
  133. Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. Neurodegener Dis. 2012; 9(4):176-86.
    View in: PubMed
    Score: 0.033
  134. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord. 2011; 31(6):443-50.
    View in: PubMed
    Score: 0.031
  135. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):300-8.
    View in: PubMed
    Score: 0.031
  136. Amyloid-ß associated cortical thinning in clinically normal elderly. Ann Neurol. 2011 Jun; 69(6):1032-42.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.